Bristol Myers Squibb (BMY) Notes Payables (2009 - 2016)

Bristol Myers Squibb (BMY) has reported Notes Payables for 8 consecutive years, with $155.0 million the latest figure, recorded in Q2 2016.

• On a quarterly basis, Notes Payables fell 79.47% year-over-year to $155.0 million in Q2 2016; TTM through Jun 2016 was $155.0 million, a 79.47% decrease from a year earlier, with the FY2015 full-year figure at $139.0 million, down 76.44% from the prior year.
• Notes Payables was $155.0 million for Q2 2016 at Bristol Myers Squibb, up from $106.0 million in the prior quarter.
• Over five years, Notes Payables peaked at $1.4 billion in Q1 2013 and troughed at $106.0 million in Q1 2016.
• A 5-year average of $494.3 million and a median of $383.0 million in 2014 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables jumped 846.21% in 2013 and plunged 79.52% in 2014, its largest moves.
• Over 5 years, Notes Payables stood at $826.0 million in 2012, then slumped by 56.54% to $359.0 million in 2013, then jumped by 64.35% to $590.0 million in 2014, then tumbled by 76.44% to $139.0 million in 2015, then advanced by 11.51% to $155.0 million in 2016.
• The last three Notes Payables figures came in at $155.0 million (Q2 2016), $106.0 million (Q1 2016), and $139.0 million (Q4 2015), per Business Quant data.